$35.50
+0.35 (+1.00%)
Open$35.34
Previous Close$35.15
Day High$36.08
Day Low$35.11
52W High$33.79
52W Low$12.73
Volume—
Avg Volume671.1K
Market Cap1.64B
P/E Ratio—
EPS$-2.75
SectorBiotechnology
Analyst Ratings
Strong Buy
14 analysts
Price Target
+27.8% upside
Current
$35.50
$35.50
Target
$45.36
$45.36
$37.53
$45.36 avg
$61.85
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 113.88M | 95.31M | 574.93M |
| Net Income | -159,221,473 | -119,935,826 | 29.33M |
| Profit Margin | -139.8% | -132.8% | 5.1% |
| EBITDA | -129,204,924 | -102,732,405 | 65.79M |
| Free Cash Flow | — | — | 30.48M |
| Rev Growth | +19.5% | +19.5% | -7.8% |
| Debt/Equity | — | — | 0.68 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.93 | +0.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $352.99 | +1.72% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.88 | +0.66% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $478.81 | +2.22% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $626.31 | +1.34% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $300.33 | +4.22% | 64.3 | 37.13B |